Press release
Fabry Disease Treatment (2021-2030) | Potential growth, attractive valuation make it is a long-term investment | Top Key Players: Sanofi S.A., Shire Plc, Amicus Therapeutics Inc.
Fabry disease also known as Anderson-Fabry disease an alpha-galactosidase-A insufficiency is an X-linked, genetic, lysosomal storage disease caused owing to the scarcity of an enzyme α galactosidase A. The mutated gene results in the formation of lipids to harmful levels in several parts of body such as the autonomic nervous system, cardiovascular system, eyes, and kidneys. The rising adoption of new therapies such as chaperone treatment is obtaining prominence due to its efficacy, which is expected to be a vital factor which can boost the fabry disease market.The global fabry disease treatment market in 2020 was approximately USD 2.7 million. The market is expected to grow at a CAGR of 7.7% and is anticipated to reach around USD 3.2 million by 2025. The escalating demand for messenger RNA (mRNA) as another effectual treatment method for Fabry disease is likely to favor the market growth during the forecast period. Several other factors such as technological development in research activities and developing healthcare infrastructure are projected to be other causes which can enhance the demand for treatment and fuel the market. Moreover, the less diagnostic rate owing to unavailability of such diagnostic procedures and trained professionals are likely to impede the market growth.
To get a holistic SAMPLE of the report, please click @ https://www.supplydemandmarketresearch.com/home/contact/1563348?ref=Sample-and-Brochure&toccode=SDMRPH1563348
The market for fabry disease treatment is intensely competitive and is highly fragmented. The vendors in the biodegradable mulch film market compete based on product portfolio, product differentiation, applications, and the pricing of products.
The rise in technological innovations in designing the products for better quality, ease of use and better performance is expected to continue to intensify the level of competition among the companies to expand their product portfolios by incorporating innovative features, into their product. Key players in the market are Sanofi S.A., Shire Plc, Amicus Therapeutics Inc., SU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Protalix Biotherapeutics Inc., Idorsia Pharmaceuticals Ltd., Avrobio Inc., Greenovation Biotech GmbH, Moderna Therapeutics Inc., & Green Cross Pharma Pte Ltd.
To get this report at a profitable rate @ https://www.supplydemandmarketresearch.com/home/contact/1563348?ref=Discount&toccode=SDMRPH1563348
Based On The Basis Of Application, The Global Fabry Disease Treatment Market Segmented Into
Hospital
Clinic
Others
Based On The Basis Of Product, The Global Fabry Disease Treatment Market Segmented Into
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)
Others
Based On The Basis Of Region, The Global Fabry Disease Treatment Market Segmented Into
Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru]
The Global Fabry Disease Treatment Market By Market Players:
Sanofi S.A.
Shire Plc.
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Greenovation Biotech GmbH
Moderna Therapeutics Inc.
Green Cross Pharma Pte Ltd.
Others
Buy Complete Copy of this Report Avail 20% Discount Use Coupon [SDMR20] @ https://www.supplydemandmarketresearch.com/home/purchase?code=SDMRPH1563348
The customization research services cover the additional custom report features such as additional regional and country level analysis as per the client requirements.
Contact Us:
SUPPLY DEMAND MARKET RESEARCH
Mr. Charles Lee
302-20 Misssisauga Valley Blvd, Missisauga,
L5A 3S1, Toronto, Canada
Phone Number: +12764775910
Email- info@supplydemandmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Treatment (2021-2030) | Potential growth, attractive valuation make it is a long-term investment | Top Key Players: Sanofi S.A., Shire Plc, Amicus Therapeutics Inc. here
News-ID: 2331773 • Views: …
More Releases from Supply Demand Market Research

South Korea Flounder Market Anticipated to grow at a CAGR of 8% from 2023-2030
The South Korea flounder is anticipated to grow at a CAGR% of 8.0% from 2022-2030. The factors contributing towards the high growth are flounders such as halibut and turbot high-protein and low-calorie food, helps to re-solve the nutritional imbalance from diet because of its rich minerals, carbohydrates and vitamins despite low-calorie. They also offer medical benefits as liver of halibut contains lots of vitamin B1 and B2, which is effective…

Global Flounder Market Anticipated to reach USD 56 Billion by 2030
The global flounder market is anticipated to reach USD 56 Billion by 2030, growing at a CAGR% of 8.0% from 2022-2030. The factors contributing towards the high growth are flounders such as halibut and turbot high-protein and low-calorie food, helps to re-solve the nutritional imbalance from diet because of its rich minerals, carbohydrates and vitamins despite low-calorie. They also offer medical benefits as liver of halibut contains lots of vitamin…

Global Seafood Market Anticipated to reach USD 730 Billion by 2030
The global seafood market is anticipated to reach USD 730 Billion by 2030, growing at a CAGR% of 8.9% from 2022-2030. The factors contributing towards the high growth are increased disposable income, awareness of fish being used as an ingredient in healthy food is growing. USA the government plans to sanction illegal fishing activities, actively promote fair trade, and promote strategies to promote the fishing industry through detailed strategies such…

Robotic Palletizers Market Is Expected to Reach US$11.98 Billion by 2033
The global robotic palletizers market is anticipated to reach $11.98 billion by 2033, presenting a 2023-2033 CAGR of 8.3%. The factors contributing towards the growth include the emerging Industry 4.0, a large scope for AI innovation, an increasing adoption of advanced industrial robotics to improve productivity and safety in manufacturing sectors, and the increasing government initiatives.
The report is highlighted with 122 tables and 96 figures, this 209-page report "Global Robotic…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…